The Biology of Brain Metastasis

Cancer Journal (United States)

Volumn 21, Issue 4, 2015, Pages 284-293

  Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Astrocytes; biologic heterogeneity; blood brain barrier; brain microenvironment; metastasis; seed and soil; selection

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; OXYGEN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN; BRAIN BLOOD VESSEL; BRAIN CANCER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DIFFUSION COEFFICIENT; DRUG EFFICACY; HUMAN; ISOTOPE LABELING; MELANOMA; MELANOMA B16; MICROGLIA; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; TUMOR CELL; TUMOR GENE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; MOUSE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SECONDARY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICROGLIA; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938598684     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000126     Document Type: Review

References (145)

1. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978;38:2651-2660.
2. Talmadge JE, Fidler IJ. AACR Centennial Series: The biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649-5669.
3. Nathoo N, Chahlavi A, Barnett GH, et al. Pathobiology of brain metastasis. J Clin Pathol. 2005;58:237-242.
4. Landis SH,Murray T, Bolden S, et al. Cancer statistics, 1998. CACancer J Clin. 1998;48:6-29.
5. Sawaya RBR, Lang FF. Metastatic brain tumors. New York: Churchill-Livingstone; 2001:999-1026.
6. Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol. 2005;18:654-661.
7. Conrad CA. Chemotherapy for metastatic tumors to the central nervous system. Curr Oncol Rep. 2001;3:490-494.
8. DeAngelis LM, Posner JB. Brain metastasis. In: Kuffe DW, Pollock RE, Weichselbaum RR, et al., eds. Cancer Medicine. 6th ed. Hamilton, Ontario: BC Decker; 2003:1227-1231.
9. Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer. 1995;76:232-236.
10. Del Regato JA. Pathways ofmetastatic spread ofmalignant tumors. Semin Oncol. 1977;4:33-38.
11. Weiss L. The cell periphery, metastasis and other contact phenomena. Frontiers Biol. 1967;7:28-332.
12. Weiss L. Biophysical aspects of the metastatic cascade. In: Weiss L, ed. Fundamental Aspects ofMetastasis. Amsterdam: North Holland Publishing Co; 1976:51-70.
13. Zeidman I. Metastasis: a reviewof recent advances. Cancer Res. 1957;17: 157-162.
14. Fisher ER, Fisher B. Recent observations on the concept of metastasis. Arch Pathol. 1967;83:321-324.
15. Fidler IJ. The relationship of embolic homogeneity, number, size, and viability to the incidence of experimental metastasis. Eur J Cancer. 1973;9: 223-227.
16. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984;3:99-116.
17. Gay LJ, Felding-Habermann B. Contribution of platelets to tumor metastasis. Nat Rev Cancer. 2011;11:123-134.
18. Jain S, ZukaM, Liu J, et al. Platelets glycoprotein IIa supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104:9024-9028.
19. Fidler IJ. Immune stimulation-inhibition of experimental cancer metastasis. Cancer Res. 1974;34:491-498.
20. Nicolson GL, Brunson KW. Organ specificity of malignant B16 melanomas: in vivo selection for organ preference of blood-borne metastasis. Gann Monograph Cancer Res. 1977;20:15-24.
21. Baserga R, Saffiotti U. Experimental studies on histogenesis of bloodborne metastases. Arch Pathol. 1955;59:26-34.
22. Chew EC, Josephson RL, Wallace AC. Morphologic aspects of the arrest of circulating cancer cells. In: Weiss L, ed. Fundamental Aspects of Metastasis. Amsterdam: North Holland Publishing Co; 1978:543-545.
23. Warren BA. Environment of the blood-borne tumor embolus adherent to vessel wall. J Med. 1973;4:150-177.
24. Woods JR. Experimental studies of the intravascular dissemination of ascetic V2 carcinoma cells in the rabbit, with special reference to fibrinogen and fibrinolytic agents. Bull Schweiz Akad Med Wiss. 1964;20:92-121.
25. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976;36: 889-894.
26. Zeidman I. The fate of circulating tumor cells. I. Passage of cells through capillaries. Cancer Res. 1961;21:38-39.
27. Zeidman I, Buss JM. Transpulmonary passage of tumor cell emboli. Cancer Res. 1952;12:731-733.
28. Hilgard P. The role of blood platelets in experimental metastases. Br J Cancer. 1973;28:429-436.
29. Ozaki T, Yoshida K, Ushijima K, et al. Studies on the mechanisms of invasion in cancer. II. In vivo effects of a factor chemotactic for cancer cells. Int J Cancer. 1971;7:93-100.
30. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2-deoxyuridine. J Natl Cancer Inst. 1970;45:733-782.
31. Fidler IJ. Selection of successive tumor lines to metastasis. Nat New Biol. 1973;242:148-149.
32. Luria SE, Delbrück M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943;28:491-511.
33. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977;197:893-895.
34. Kripke ML. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res. 1977;37: 1395-1400.
35. Kripke ML, Gruys E, Fidler IJ. Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res. 1978;38:2962-2967.
36. Paget S. The distribution and fate of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1889;8:98-101.
37. Ewing J. Neoplastic Diseases. 6th ed. Philadelphia, PA: WB Saunders Co; 1928.
38. Aukerman SL, Price JE, Fidler IJ. Different deficiencies in the prevention of tumirgenic-low-metastatic murine K-1735 melanoma cells from producing metastases. J Natl Cancer Inst. 1986;77:915-924.
39. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 1980;40:1281-1287.
40. Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastasis. Science. 1982;217:361-363.
41. Tarin D, Price JE, Kettlewell MG, et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 1984;44:3584-3591.
42. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture. Cancer Res. 1990; 50:6130-6138.
43. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited (Timeline). Nat Rev Cancer. 2003;3:453-458.
44. Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumour population. Nature. 1982;297:593-594.
45. Hu FN, Wang RY, Hsu TC. Clonal origin of metastasis in B16 murine melanoma: a cytogenetic study. J Natl Cancer Inst. 1987;78:155-159.
46. Fidler IJ. Modulation of the organ miocroenvironment for treatment of cancer metastasis. J Natl Cancer Inst. 1995;87:1588-1592.
47. Schackert G, Fidler IJ. Development of in vivo models for studies of brain metastasis. Int J Cancer. 1988;41:589-594.
48. Fujimaki T, Fan D, Staroselsky A, et al. Critical factors regulating sitespecific brain metastasis of murine melanomas. Int J Oncol. 1993;3: 789-799.
49. Tsukada T, Fouad A, Pickren JW. Central nervous system metastasis from breast carcinoma: autopsy study. Cancer. 1983;52:2349-2354.
50. Zhang RD, Price JE, Schackert G, et al. Malignant potential of cells isolated from lymph node or brain metastases of melanoma patients and implications of prognosis. Cancer Res. 1991;52:2029-2035.
51. Li L, Price JE, Fan D, et al. Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J Natl Cancer Inst. 1989;81:1406-1412.
52. Guo L, Fan D, Zhang F, et al. Selection of brain metastasis-initiating breast cancer cells according to growth on hard agar. Am J Pathol. 2011; 178:2357-2366.
53. Soffietti R, Rud R, Mutani R. Management of brain metastases. J Neurol. 2002;249:1357-1369.
54. Schouten IJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698-2705.
55. Kornblith PL, alker MD, Cassady JR. Neoplasms of the central nervous system. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Priactice of Oncology. 2nd ed. Philadelphia: JB Lippincott; 1985:1437-1566.
56. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43: 3427-3433.
57. Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199-207.
58. Schackert G, Fidler IJ. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res. 1988;48:3478-3484.
59. Fujimaki T, Price JE, Fan D, et al. Selective growth of human melanoma cells in the brain parenchyma of nude mice. Melanoma Res. 1996;6: 363-371.
60. Tsukuda T, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma: autopsy study. Cancer. 1983;52:2349-2354.
61. Fidler IJ, Yano S, Zhang RD, et al. The seed and soil hypothesis: vascularization and brain metastasis (Personal View). Lancet Oncol. 2002;3: 53-57.
62. Patan S. Tie1 and Tie2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res. 1998;56:1-21.
63. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408-1416.
64. Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000;60:4959-4967.
65. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs angiopoietin-1 and matrix metalloproteinases. Cancer Cell. 2004;6:529-531.
66. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
67. Stewart PA, Hayakawa K, Farrell CL, et al. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue: evidence for a blood-brain barrier defect. J Neurosurg. 1987;67:697-705.
68. Tannock IF. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer. 1968;22: 258-273.
69. Russ JC. Uses of the Euclidean distance map for the measurement of features in images. J Comp Assist Miscrosc. 1989;1:343-375.
70. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46:149-168.
71. Russ JC. The Image Processing Handbook. 2nd ed. BocaRaton, FL: CRC Press; 1995:463-469.
72. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via a specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
73. Tomlinson E. Theory and practice of site-specific drug delivery. Adv Drug Del Rev. 1987;1:187-198.
74. Johansson BB. The physiology of the blood-brain barrier. Adv Exp Med Biol. 1990;274:25-39.
75. Gregoire N. The blood-brain barrier. J Neuroradiol. 1989;16:238-250.
76. Pardridge WM, Oldendorf WH, Cancilla P, et al. Blood-brain barrier: interface between internal medicine and the brain clinical conference. Ann Intern Med. 1986;105:82-95.
77. Felgenhauer K. The blood-brain barrier redefined. J Neurol. 1986;233: 193-194.
78. Shapiro WR, Shapiro JR. Principles of brain tumor chemotherapy. Semin Oncol. 1986;13:56-69.
79. Steward PA, Hayakawa K, Farrell CL, et al. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg. 1987;67:697-705.
80. Zagzag D, Goldenberg M, Brem S. Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. AJR Am J Roentgenol. 1989;153:141-146.
81. Vriesendorp FJ, Peagram C, Bigner DD, et al. Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats. J Natl Cancer Inst. 1987;79:123-130.
82. Iannotti F, Fleschi C, Alfano B, et al. Simplified, noninvasive PET measurement of blood brain barrier permeability. J Comput Assist Tomogr. 1987;11:390-397.
83. Frong D, Israel O, Kohn S, et al. The blood-tissue barrier of human brain tumors: correlation of scintigraphic and ultrastructural findings (concise communication). J NuclMed. 1984;25:461-465.
84. Kohn S, Front D, Nir I. Blood-brain barrier permeability of human gliomas as determined by quantitation of cytoplasmic vesicles of the capillary endothelium and scintigraphic findings. Cancer Invest. 1989;7:313-321.
85. Nir I, Levanon D, Iosilevsky G. Permeability of blood vessels in experimental gliomas: uptake of 99Tc-glucoheptonate and alteration in bloodbrain barrier as determined by cytochemistry and election microscopy. Neurosurgery. 1989;25:523-532.
86. Zuelch KG. Brain Tumors: Their Biology and Pathology. 3rd ed. Berlin: Springer-Verlag; 1986:480-498.
87. Sawaya R, Bindal R, Lang FF. Metastatic brain tumors. In: Kaye AH, Laws EE, eds. Brain Tumors. New York: Churchill-Livingstone; 2001: 99-1026.
88. Genka S, Deutsch J, Stahle PL, et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoamide mustard in the rat. Cancer Chemother Pharmacol. 1990;27:1-7.
89. Greig NH, Soncrant TT, Shetty HU, et al. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol. 1990;26:263-268.
90. Owman C, Hardebo JE. Functional heterogeneity of the cerebrovascular endothelium. Brain Behav Evol. 1988;32:65-75.
91. Fenstermacher J, Gross P, Sposito N, et al. Structural and functional variations in capillary systems within the brain. Ann N Y Acad Sci. 1988;529: 21-30.
92. Baur HC, Tontsch U, Amberger A, Bauer H. Gamma-glutamyl-transpeptidase (GGTP) and NA+K(+)-ATPase activities in different subpopulations of cloned cerebral endothelial cells: responses to glial stimulation. Biochem Biophys Res Commun. 1990;168:358-363.
93. Nakagawa Y, Fujimoto N, Matsumoto K, et al. Morphologial changes in acute cerebral ischemia after occlusion and reperfusion in the rat. Adv Neurol. 1990;52:21-27.
94. Kawamura S, Schürer L, Goetz A, et al. An improved closed cranial window technique for investigation of blood-brain barrier function and cerebral vasomotor control in the rat. Int JMicrocirc Clin Exp. 1990;9:369-383.
95. Malmgren LT, Olsson Y. Differences between the peripheral and the central nervous system in permeability to sodium fluoresein. J CompNeurol. 1980;191:103-117.
96. Zhang RD, Price JE, Fujimaki T, et al. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol. 1992;141:1115-1124.
97. Dietrich WD, Busto R, Hailey M, et al. The importance of brain temperature in alterations of the blood-brain barrier following cerebral ischemia. J Neuropathol Exp Neurol. 1990;49:486-497.
98. Schackert G, Simmons RD, Buzbee TM, et al. Macrophage infiltration into experimental brain metastases: occurrence through an intact bloodbrain barrier. J Natl Cancer Inst. 1988;80:1027-1034.
99. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656-661.
100. Lawson LJ, Perry VH, Dri P, et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39:151-170.
101. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005; 308:1314-1318.
102. DavalosD, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752-758.
103. Perry VH, Hume DA, Gordon S. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. Neuroscience. 1985;15:313-326.
104. Alliot F, Marty MC, Cambier D, et al. A spontaneously immortalized mouse microglial cell line expressing CD4. Brain Res Dev Brain Res. 1996;95:140-143.
105. Hume DA, Perry VH, Gordon S. Immunohistochemical localization of a macrophage-specific antigen in developing mouse retina: phagocytosis of dying neurons and differentiation of microglial cells to form a regular array in the plexiform layers. J Cell Biol. 1983;97:253-257.
106. He BP,Wang JJ, Zhang X, et al. Differential reactions ofmicroglia to brain metastasis of lung cancer. Mol Med. 2006;12:161-170.
107. Langley RR, Fan D, Guo L, et al. Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis. Int J Oncol. 2009;35:665-672.
108. Morantz RA,WoodGW, FosterM, et al. Macrophages n experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg. 1979;50:305-311.
109. Morantz RA, Wood GW, Foster M, et al. Macrophages in experimental and human brain tumors. Part 1: Studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J Neurosurg. 1979;50:298-304.
110. Zhang M, Olsson Y. Reactions of astrocytes and microglial cells around nonreactivity in reactive astrocytes and activation of microglial cells. J Neurol Sci. 1995;134:26-32.
111. Brantley EC, Guo L, Zhang C, et al. Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl Oncol. 2010;3:380-388.
112. Xie K, Huang S, Dong Z, et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med. 1995;181:1333-1343.
113. Rock RB, Gekker G, Hu S, et al. Role of microglia in central nervous system infections. Clin Microbiol Rev. 2004;17:942-964.
114. Eue I, Kumar R, Dong Z, et al. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipiopeptide JNT3002 encapsulated in liposomes. J Immunother. 1998;21: 341-351.
115. Xie K, Huang S, Dong Z, et al. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res. 1995;55:3123-3131.
116. Gibbons HM, Dragunow M. Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide. Brain Res. 2006; 1084:1-15.
117. Kim SJ, Kim JS, Papadopoulos J, et al. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol. 2009;174:1972-1980.
118. Ransohoff RM, Perry VH.Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119-145.
119. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience. 2009;158:1030-1038.
120. Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000;60:4959-4967.
121. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25:2306-2312.
122. KamounWS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27:2542-2552.
123. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38:1277-1287.
124. Sawaya R, Bindal R, Lang FF. Metastatic brain tumors. In: Kaye AH, Laws EE, eds. Brain Tumors. New York: Churchill-Livingstone; 2001: 999-1026.
125. Abbott N. Astrocytes-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200:629-638.
126. Seth P, Koul N. Astrocyte, the star avatar: redefined. J Biosci. 2008;33: 405-421.
127. Koehler RC, Gebremedhin D, Harder DR. Role of astrocytes in cerebrovascular regulation. J Appl Physiol (1985). 2006;100:307-317.
128. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007;10:1369-1376.
129. Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006;86:1009-1031.
130. Nedergarrd M. Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. Science. 1994;263:1768-1771.
131. Verkhratsky A, Kirchhoff F. Glutamate-mediated neuronal-glial transmission. J Anat. 2007;210:651-660.
132. Gee JR, Keller JN. Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol. 2005;37:1145-1150.
133. Wang XF, Cynader MS. Pyruvate released by astrocytes protects neurons from copper-catalyzed cystein neurotoxocity.JNeurosci. 2001;21:3322-3331.
134. Faulkner JR, Herrmann JE,WooMJ, et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci. 2004;24: 2143-2155.
135. TrendelenburgG,DirnaglU. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia. 2005;51:307-320.
136. Lin Q, Balasubramanian K, Fan D, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction channels. Neoplasia. 2010;12:748-754.
137. Kim SJ, Kim JS, Park ES, et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia. 2011; 13:286-298.
138. Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci. 2005;6:262-640.
139. Kasischke KA, Vishwasrao HD, Fisher PJ, et al. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science. 2004;305:99-103.
140. Desagher S, Glowinski J, Premont J. Astrocytes protect neurons from hydrogen peroxide toxisity. J Neurosci. 1996;16:2553-2562.
141. SofroniewMV. Reactive astrocytes in neural repair and protection. Neuroscientist. 2005;11:400-407.
142. PeknyM,Nilsson M. Astrocyte activation and reactive gliosis. Glia. 2005; 50:427-434.
143. Goldberg GS, Moreno AP, Bechberger JF, et al. Evidence that disruption of connexin particle arrangements in gap junction plaques is associated with inhibition of gap junctional communication by a glycyrrherinic acid derivative. Exp Cell Res. 1996;222:48-53.
144. Guan X, Wilson S, Schlender KK, et al. Gap-junction disassembly and connexin 43 dephosphorylation induced by 18 -glycyrrhetinic acid. Mol Carcinog. 1996;16:157-164.
145. Roderick HL, Cook SJ. Ca2+ signaling checkpoints in cancer: remodeling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008;8: 361-375.